© Translational Andrology and Urology. All rights reserved. Transl Androl Urol, 2016;5(S1) tau.amegroups.com Cite this abstract as: Cui J, Chen S, Yang Y, Zhu Y, Chen F, Shi B. Combination of intravesical chemotherapy and Bacillus Calmette-Guerin versus Bacillus Calmette-Guerin monotherapy in intermediateand high-risk non-muscle invasive bladder cancer: a systematic review and meta-analysis. Tr...

Despite the long history of the worldwide use of Bacillus Calmette-Guerin (BCG) vaccine, a wide spectrum of adverse reactions has been observed in a small proportion of immunized infants; the most severe complication, disseminated BCGitis, is often fatal but exceedingly rare and is considered to result from host immunodeficiency. At present, CT scan, ultrasound, X-ray and bone marrow aspi...

Bacillus Calmette-Guerin (BCG),4 an attenuated strain of Mycobacterium bovis, was developed as a vaccine against human tuberculosis by Calmette and Guerin at the Pasteur Institute in 1908. BCG has recently regained the spotlight in completely different roles, that of an immunological adjuvant and "'antitumor" agent. Investigations with this agent in the immunotherapy of cancer have met with var...

The Calmette--Guerin Bacillus (BCG), an attenuated live strain of Mycobacterium bovis was originally developed by Albert Leon Charles Calmette and Camile Guerin in 1925 as a vaccine for tuberculosis. At the present, BCG is widely used as a complementary therapy for superficial bladder neoplasms. This treatment is considered to be safe and well tolerated although local and distal complications m...

Various treatments have been used to decrease the risk of suppuration; the most troublesome complication of Calmette-Guerin bacillus adenitis, but results are controversial. Metaanalysis of four randomized controlled trials revealed no significant difference in the frequency of suppuration between the treatment and control groups for all treatments [relative risk (RR), 1.10; 95% confidence inte...

We report a case of chest wall abscess caused by Mycobacterium bovis BCG that arose as a complication 1 year after intravesical BCG instillation. We identified M. bovis BCG Tokyo 172 in the abscess by PCR-based typing of Mycobacterium tuberculosis complex and analysis of variable number of tandem repeats data.

The molecular fingerprints of 1,349 isolates of Mycobacterium bovis received between 1979 and August 2000 at Agence Française de Sécurité Sanitaire des Aliments (Afssa) have been obtained by spoligotyping. The majority of the isolates (1,266) were obtained from cattle living in France. An apparently high level of heterogeneity was observed between isolates. One hundred sixty-one spoligotypes we...

Tuberculosis is rising in the developing world due to poor health care, human immunodeficiency virus type 1 infection, and the low protective efficacy of the Mycobacterium bovis BCG vaccine. A new vaccination strategy that could protect adults in the developing world from tuberculosis could have a huge impact on public health. We show that BCG boosted by poxviruses expressing antigen 85A induce...

This is the first identified case of Mycobacterium bovis bacillus Calmette-Guerin (BCG)-derived cutaneous tuberculosis that localizes at a place different from the vaccination site in hosts without immune deficiency. A healthy baby with a developing abscess is described. A multiplex PCR identified the abscess as originating from M. bovis BCG Tokyo 172.